Personal Health Large Language Models: HealthTech Trend to watch in 2026

Nelson Advisors
Aug 30
17 min read

Updated: Aug 31

Personal Health Large Language Models: HealthTech Trend to watch in 2026

Executive Summary

The year 2026 is poised to be a pivotal year for the integration of artificial intelligence into healthcare, marked by the maturation of a new class of specialised systems known as Personal Health Large Language Models (PH-LLMs). These models represent a fundamental shift beyond general-purpose AI, moving from broad-based utility to domain-specific reliability. They are positioned to revolutionise the HealthTech landscape by acting as intelligent, reasoning engines that enhance both the patient journey and the efficiency of healthcare providers.

The analysis reveals several key findings. First, the market for AI in healthcare is experiencing explosive and consistent growth, with varying projections consistently pointing toward a multi-hundred-billion-dollar valuation in the near term. This growth is buoyed by significant venture capital funding, with AI-enabled startups capturing the majority of investment dollars and commanding a substantial premium in deal size. Second, PH-LLMs are a new category of fine-tuned, customisable models engineered to understand and reason over diverse, multi-modal data, including wearable sensor outputs and electronic health records (EHRs).

This technical foundation enables them to provide highly precise, personalised insights. Third, the primary value propositions for this technology are dual-pronged: they empower patients with proactive wellness coaching and symptom analysis while simultaneously addressing the critical issue of provider burnout through automated clinical documentation and workflow support. Fourth, the ecosystem is characterized by a dynamic interplay between established tech giants like Google, which are developing foundational models, and a robust field of well-funded startups like Hippocratic AI and Abridge, which are cornering high-return use cases.

However, the path to widespread adoption is not without significant challenges. The report identifies critical risks related to data privacy, algorithmic bias, and accountability, which are being addressed by new regulatory frameworks from the U.S. Food and Drug Administration (FDA) and the European Union (EU). Controversial pilot programs, such as the one in Medicare, also underscore the high-stakes ethical and political debates surrounding AI's role in clinical decision-making. To navigate this complex environment, stakeholders must adopt a strategic approach. This includes focusing investment on specialized, compliant solutions, building AI systems with safety and transparency at their core, and implementing phased, well-governed integration plans within healthcare organisations.

The Foundational Shift: Defining Personal Health Large Language Models (PH-LLMs)

PH-LLMs vs. General-Purpose LLMs

General-purpose Large Language Models (LLMs) are AI algorithms built on deep learning techniques and trained on vast, general datasets to understand and generate human-like text. These models, exemplified by tools like ChatGPT, are highly versatile and possess a broad range of pre-trained knowledge, making them useful for a wide array of applications. However, their inherent design presents significant drawbacks, particularly in a high-stakes domain like healthcare. Training and usage can be computationally expensive and time-consuming, and their outputs are prone to "hallucinations", the generation of incorrect or nonsensical information, which can lead to the spread of misinformation. Furthermore, due to their training on generalised data, these models lack domain-specific expertise, which makes them unreliable for specialised applications and can perpetuate ethical biases present in the human-produced data they were trained on.

The healthcare market is responding to these limitations with the emergence of Personal Health Large Language Models (PH-LLMs), a new class of customisable LLMs fine-tuned on domain-specific data to provide precise and contextually aware responses for specialised applications. Google's PH-LLM, for example, is a version of Gemini that has been fine-tuned for text understanding and reasoning over numerical time-series personal health data from applications in sleep and fitness.

This fine-tuning process allows PH-LLMs to achieve improved accuracy, reduced bias, and greater efficiency for niche tasks.The market is not simply adopting generic LLMs; it is rapidly moving toward highly specialised, fine-tuned PH-LLMs. The fundamental reason for this transition is the simple fact that the drawbacks of general LLMs, such as hallucinations and lack of domain expertise, are unacceptable in a clinical context where errors can have severe consequences. The development and validation of PH-LLMs against expert benchmarks is a direct market response to the demand for trust and reliability, transforming the technology from a convenient tool into a dependable medical instrument. This strategic transition explains why investors are channeling significant capital into companies with specialised AI solutions rather than just generic applications.

The following table provides a comparative analysis to highlight the functional distinctions between these different types of AI systems.

Feature	Traditional Health Apps	General-Purpose LLMs	Personal Health LLMs (PH-LLMs)
Data Scope	Structured, manual input (e.g., calorie counting, step tracking)	Vast, public, and unstructured datasets	Specialised, multi-modal data (e.g., EHRs, wearables, biomarkers, text)
Core Function	Predefined functions, goal tracking, and progress visualisation	Broad language understanding and generation for general queries	Reasoning and inference over integrated data for personalised insights
Key Advantage	Simplicity and structured guidance	Versatility and extensive general knowledge	Domain-specific expertise, precision, and accuracy
Drawback	Lacks personalisation, siloed data, and limited interactivity	Prone to hallucinations, lacks domain expertise, and high computational cost	High data dependency, development cost, and regulatory complexity
Primary Use Case	Weight loss, fitness tracking, and medication reminders	General health information, content creation, and administrative support	Patient coaching, clinical decision support, and administrative automation

The Distinction from Traditional Health Apps and Telemedicine

Personal Health LLMs represent a new paradigm that is distinct from existing health apps and telemedicine platforms. A traditional health app is typically a structured, goal-oriented tool that provides predefined exercises, tracks progress, and offers information without a deep reasoning capability over complex, integrated data. Similarly, telemedicine is best understood as a delivery mechanism, the use of telecommunications technologies like videoconferencing to deliver remote clinical services—rather than a core intelligence layer.While telemedicine has helped overcome geographical barriers, it has also struggled to handle the high volume of patient inquiries, highlighting the need for an underlying layer of intelligence.

PH-LLMs fill this gap by acting as a new intelligence layer that will permeate and fundamentally transform these existing systems. Unlike a generic app that can tell a user their average heart rate, a PH-LLM can integrate a user's heart rate trends, sleep data, and exercise logs from wearable sensors to generate a personalised, conversational insight about how a specific physical activity on a certain day may have impacted their physiological response. This is demonstrated by the PhysioLLM system, which integrates physiological data from wearables with contextual information to provide a comprehensive statistical analysis. A user study found that PhysioLLM was superior to both the Fitbit App and a generic LLM chatbot in facilitating a deeper, personalised understanding of health data and supporting actionable steps.

The technology also acts as a critical intermediary in telemedicine, where it can automate initial patient assessments, summarise key medical information for clinicians, and even overcome language barriers to create a more cohesive care ecosystem.The future of HealthTech is a symbiotic relationship between data collection (wearables, EHRs), the delivery channel (telemedicine), and the reasoning engine (PH-LLM), which moves the user from a passive data viewer to an active participant in their health journey.

The Technical and Functional Architecture of PH-LLMs

The core of a Personal Health LLM's capability lies in its technical and functional architecture. These models are built on a foundation of multi-modal LLMs, such as Gemini, which are then fine-tuned on domain-specific data to achieve superior performance. This fine-tuning process incorporates the integration of analytical tools for specific domains, such as the ability to analyse nutritional intake for diabetic patient management or to interpret Photoplethysmography (PPG) signals from wearables for heart rate estimation.

This technical foundation gives rise to a set of key capabilities that distinguish PH-LLMs:

Data Integration: PH-LLMs can seamlessly ingest and reason over disparate data types, including unstructured text (notes, queries), numerical time-series data (from wearables), and structured data (EHRs, biomarkers).This multi-modal capability allows them to process a complete, real health data profile to answer queries.
Personalised Insight Generation: By integrating and analysing this data, PH-LLMs can produce individualised recommendations and insights tailored to a user's specific health needs and goals. For instance, they can provide customised recipes that fit a client's nutritional needs and dietary restrictions.
Reasoning and Inference: These models are not just conversational agents; they have the ability to perform complex calculations and make sophisticated inferences. They can suggest potential diagnoses and recommend treatment plans based on a patient's unique data set, distilling complex patient narratives into actionable insights. A study comparing the openCHA framework with GPT-4 in diabetic patient management found that the openCHA model, which integrated domain-specific knowledge, achieved a 92.1% accuracy rate, significantly outperforming GPT-4's 51.8% accuracy on the same questions. This demonstrates the power of fine-tuning and specialised architecture to exceed the performance of generic models.

The Core of the Trend: Use Cases and Value Propositions

Enhancing the Patient Journey: From Symptom Checking to Personalised Coaching

Personal Health LLMs are creating a new category of proactive, preventative, and continuous care that blurs the lines between consumer-facing wellness and clinical medicine. One of the most immediate applications is in symptom analysis and triage, where conversational AI tools act as virtual assistants to conduct initial patient interviews, analyse symptoms, and suggest appropriate next steps. This helps reduce unnecessary emergency room visits and long wait times while offering a psychological benefit, as some studies suggest patients may feel more comfortable disclosing sensitive information to an AI than a human.

A major value proposition lies in personalized wellness and coaching. By integrating data from wearable technologies and fitness trackers, PH-LLMs provide real-time feedback and suggest adaptive workout plans, personalised meal plans, and nutritional guidance that align with a user's goals and dietary habits.This approach moves the focus from reactive healthcare to proactive, continuous care, enabling the early detection of issues before they become acute conditions. PH-LLMs are also instrumental in chronic disease management and mental health support, with AI-powered chatbots and mood-tracking apps providing scalable, 24/7 support for emotional wellness and adherence to treatment plans. The ability to continuously analyse data from wearables and other sources allows for a shift away from reactive healthcare models and toward a continuous, data-driven approach that is more cost-effective and improves long-term outcomes for patients.

Empowering the Healthcare Provider: From Clinical Workflows to Decision Support

The most immediate and significant return on investment (ROI) for PH-LLMs is in streamlining provider workflows. The healthcare system is burdened by a substantial amount of administrative paperwork and data entry, with physicians reportedly spending nearly half of their time on non-clinical duties. This significant administrative burden is a major contributor to clinician burnout. LLMs directly address this problem through automated clinical documentation and ambient scribing. The technology can transcribe and summarise doctor-patient conversations in real time, automatically generating structured clinical notes, such as SOAP (Subjective, Objective, Assessment, Plan) notes, and flagging key information for inclusion in EHRs. This automation frees healthcare professionals to focus on direct patient interaction, which has been shown to reduce burnout and improve workflow efficiency. The high adoption rate of ambient scribes, hovering between 30% and 40% across physician groups, demonstrates that a clear business case for saving time and reducing administrative burden is a powerful catalyst for market penetration. This explains why funding is heavily concentrated in "non-clinical workflow" and "clinical workflow" solutions, which accounted for over half of all digital health funding in the first half of 2025.

Beyond administrative tasks, LLMs are also becoming indispensable tools for clinical decision support and diagnostic assistance. By analysing vast amounts of medical literature, clinical notes, and patient records, these models can assist in diagnosing conditions, suggesting appropriate treatment plans, and providing evidence-based recommendations. A study comparing an open-source model (Llama) with a proprietary one (GPT-4) on complex clinical cases found that Llama made a correct diagnosis in 70% of cases, compared to GPT-4's 64% accuracy. This indicates the increasing maturity of this capability and its potential to optimise clinician performance and help reduce diagnostic errors. Additionally, LLMs are being used in medical education to simulate realistic patient interactions, allowing trainees to hone their communication and diagnostic skills in a safe environment.

The Market Landscape: Growth and Investment Dynamics

Market Size and Growth Projections

The market for digital health and AI in healthcare is experiencing a period of explosive growth. While specific valuations vary across different reports, the consistent upward trajectory is undeniable. The global digital health market was valued at approximately $312.9 billion USD to $376.68 billion USD in 2024. This market is projected to reach between $1.5 trillion USD and $2.19 trillion USD by 2032–2034, representing a compound annual growth rate (CAGR) of 19.7% to 21.2% from 2025.

Within this broader market, the AI in healthcare segment is growing at a disproportionately higher rate, indicating its significant influence on the entire sector. The AI in healthcare market, valued at $27.59 billion USD to $37.98 billion USD in 2024, is projected to grow at a staggering CAGR of 37% to 38.5% and reach over $600 billion USD by 2034. North America currently dominates the market, accounting for over 54% of revenue in 2024, with the U.S. alone valued at over $123.6 billion USD. However, the Asia-Pacific region is a quickly growing market, and South America is focusing on telehealth and remote patient monitoring, indicating a global proliferation of AI-driven solutions.

Digital Health & AI Market Projections (2024-2034)

Market Segment	2024 Value (USD)	2034 Forecast (USD)	CAGR (2025-2034)	Key Trend
Digital Health	$312.9B - $376.68B	$1.5T - $2.19T	19.7% - 21.2%	Rapid adoption of telehealth, AI-based tools, and wearables
AI in Healthcare	$27.59B - $37.98B	$674.19B	37% - 38.5%	Higher growth rate than broader market; significant investment in AI-enabled startups

Investment Trends in HealthTech AI

Venture capital funding for AI-enabled startups in the digital health sector is the primary financial driver of the current market momentum. In the first half of 2025, digital health VC funding reached $6.4 billion USD, with AI-enabled startups capturing the lion's share at 62% of the total, or $3.95 billion USD. These companies are commanding a significant premium; the average funding per round for an AI-enabled startup was $34.4 million USD, an 83% increase compared to the 18.8 million USD average for non-AI companies.

This investment is increasingly concentrated in larger, later-stage rounds. In the first half of 2025, nine of the 11 "mega deals" (fundraises exceeding $100 million USD) went to AI-enabled startups. The top three funded value propositions were non-clinical workflow, clinical workflow, and data infrastructure, which together accounted for 55% of overall digital health funding in the first half of the year. This concentration of funding in workflow solutions underscores a clear business trend: investors are backing companies that solve immediate and painful problems, such as clinician burnout, which provide a clear and rapid ROI for healthcare systems.

The Key Players: Companies, Models and Research

The Titans of Tech

Major technology companies are leveraging their vast resources to develop foundational LLMs for healthcare. Google, for example, is a key player, having developed models like Med-PaLM 2 and the Personal Health Large Language Model (PH-LLM). Its DeepMind division is active in pharmaceutical research and development, radiology, and unstructured data analysis. These companies are building powerful, foundational models with the intent of creating a platform for more specialised applications to be built upon.

Innovating Startups

A dynamic ecosystem of startups is demonstrating that the future of HealthTech is not in monolithic, single-purpose models but in specialised, high-value applications that integrate deeply into existing systems. Hippocratic AI is an example of this approach, with its Polaris 3.0 model, a suite of 22 LLMs with 4.2 trillion parameters. The model is designed for non-diagnostic clinical tasks and has achieved a high clinical accuracy rate of 99.38%. It boasts unique capabilities such as advanced emotional intelligence, robust audio handling for real-world phone calls, and deep integrations with major EHRs like Epic and Cerner.

Another key player is Abridge, which provides an ambient AI clinical documentation tool that transforms patient-clinician conversations into structured clinical notes in real time. This tool integrates directly into EHR workflows and is designed to reduce physician burnout by automating note-taking and improving documentation quality. The investment focus on these specialised companies confirms that they are not directly competing with the tech giants; rather, they are carving out a defensible market position by creating solutions that solve a very specific pain point for providers and integrate seamlessly with existing hospital infrastructure. Other notable startups include Qure.ai for medical imaging, Biofourmis for remote patient monitoring, and Corti.ai for emergency response voice analysis. This market fragmentation suggests a future where no single company will dominate, but rather a collection of specialised, interoperable AI agents will manage different aspects of healthcare.

Pioneering Research Institutions

Academic and clinical research institutions are playing a vital role in pushing the boundaries of health LLMs. Researchers at the Boston Children's Hospital's Center for Health Information and Promotion (CHIP) are developing methods for rapid drug event detection, predictive pharmacology, and leveraging LLMs for public health initiatives. The Massachusetts Institute of Technology (MIT) focuses on developing AI technologies for the entire span of healthcare, from drug discovery to personalised care. Their research has also uncovered subtle but critical technical challenges, such as the finding that non-clinical information in patient messages, like typos or extra white space, can reduce the accuracy of medical recommendations. Stanford University's Human-Centred Artificial Intelligence (HAI) institute is leading the development of holistic evaluation frameworks, such as MedHELM, to assess medical LLMs on real-world clinical tasks rather than just standardised exam performance. This research community provides a critical foundation for validation and innovation.

Critical Considerations: Risks, Challenges and Regulations

Data Privacy and Security

The widespread adoption of Personal Health LLMs presents significant data privacy and security risks. A major concern is the potential for data leakage, particularly from the "Bring Your Own LLM" (BYO-LLM) trend, where employees may input sensitive Protected Health Information (PHI) into public LLMs without proper oversight. Unlike traditional software, LLMs learn from the data they process, and sensitive information can be inadvertently stored and exposed. Even with anonymised data, sophisticated re-identification techniques can compromise patient privacy.

To mitigate these risks, organisations must adopt a structured governance approach. This includes implementing a multi-pronged strategy with robust data anonymisation, using the principle of data minimisation (using only the minimum necessary data), and implementing strict access controls. For data in transit and at rest, strong encryption is essential. Encouraging the use of private, company-managed LLMs is a critical step to prevent data from being fed into external models.Additionally, healthcare organisations must conduct thorough due diligence on vendors and establish Business Associate Agreements (BAAs) to ensure compliance with privacy regulations like HIPAA.

Algorithmic Bias and Ethical Concerns

Algorithmic bias is an inherent risk in any machine learning model, as it reflects patterns and priorities encoded in the training data. When LLMs are trained on biased human-produced data, they can perpetuate harmful stereotypes and lead to algorithmic discrimination, which can exacerbate existing health disparities and disadvantage certain patient groups. These biases are a serious concern in clinical contexts, where they can lead to inaccurate diagnoses or inappropriate care recommendations.

To address these issues, developers and deployers must focus on active bias mitigation. This involves using diverse and representative training data, implementing bias-mitigation benchmarks to identify gaps, and providing contextual transparency about the sources and processes behind the model's outputs. The development of a governance model that emphasises "fairness, transparency, trustworthiness, and accountability" is recommended to ensure the ethical use of AI in medicine.

The Evolving Regulatory Landscape

Regulatory bodies worldwide are working to establish frameworks to govern the safe and effective use of AI in healthcare. The FDA has issued final guidance on Predetermined Change Control Plans (PCCP), which allows manufacturers of AI-enabled medical devices to make specific, foreseeable software modifications without submitting a new marketing application for each update. This approach aims to streamline innovation while ensuring that changes remain within the intended use and are properly validated. There is also a proposed bill, the Healthy Technology Act of 2025, which could potentially allow qualified AI to prescribe drugs if it is authorised by state law and approved by federal provisions.

In Europe, the AI Act, which entered into force in 2024, classifies AI systems intended for medical purposes as "high-risk". This classification subjects them to stringent requirements for risk mitigation, high-quality datasets, and human oversight. The EU's Product Liability Directive also updates liability rules for new technologies, ensuring that manufacturers can be held responsible for damages caused by a defective product, including those that learn or acquire new features after deployment.

Pilot Programs: Case Studies in Progress

The real-world application of AI is bringing these regulatory and ethical concerns to the forefront. A notable example is the controversial Medicare pilot program launched in six states that uses AI to make "prior authorisation" decisions, determining whether a procedure, such as spinal surgery, should be covered.Critics, including experts and union leaders, have likened the program to "AI death panels" and warn that it introduces the same issues seen in private insurance, where algorithms have been used to swiftly deny large batches of claims.

A particularly contentious aspect is that the private AI firms are paid a share of the savings generated from the claims they reject, which critics argue creates a significant financial incentive to maximise denials and directly puts them at odds with clinicians. This case study highlights the complex ethical and political risks that arise when AI systems are used in high-stakes clinical and financial decision-making.

Key Ethical and Regulatory Risks and Mitigation Strategies

Risk Category	Key Problem	Mitigation Strategy	Relevant Frameworks
Data Privacy & Security	Data leakage from BYO-LLM, re-identification risk of PHI	Data anonymisation, strong encryption, private LLMs, BAAs	HIPAA, GDPR, EU AI Act
Algorithmic Bias	Perpetuates harmful stereotypes and exacerbates health disparities	Diverse training data, bias-mitigation benchmarks, ethical guidelines	WHO AI principles, FDA oversight, EU AI Act
Accountability & Trust	"Black box" decisions, lack of transparency, inability to hold AI accountable	Contextual transparency, human oversight, clear liability rules	EU Product Liability Directive, FDA PCCP
Regulatory Hurdles	Rapid technological pace outstrips slow regulatory cycles	Regulatory "sandboxes," continuous education, phased implementation	FDA PCCP, EU AI Act, EHDS

The 2026 Outlook: Future Trajectories and Strategic Recommendations

Predictions for the HealthTech Ecosystem

The future of HealthTech will be characterised by a continued and deepening convergence of technologies. PH-LLMs will become increasingly integrated with wearables, genomics, and telemedicine to create truly holistic, personalised health platforms.This synergy will enable a shift from episodic, reactive care to a proactive, predictive model.

The growing maturity of open-source models, such as Llama and Me-LLaMA, which can already perform competitively with and in some cases even outperform proprietary models , is likely to accelerate innovation and reduce the reliance on a few large corporations. We can also expect to see a shift from single-purpose LLMs to complex, agentic AI systems that can autonomously handle decision-making and orchestrate entire workflows, from initial patient calls to EMR documentation.

6.2. Strategic Recommendations

To navigate the dynamic landscape of 2026, stakeholders must adopt a clear strategy.

For Investors: A focus should be placed on companies with a clear, validated business case and a strong value proposition, particularly those that offer a clear ROI for providers by automating clinical and non-clinical workflows. Additionally, investments should prioritise solutions that are building robust, HIPAA-compliant data infrastructure and governance frameworks from the ground up to mitigate legal and ethical risks.
For Startups and Developers: The strategic imperative is to build "AI-native" solutions that integrate deeply with existing clinical workflows and systems, rather than simply offering a standalone tool. Prioritising safety, explainability, and compliance from the earliest stages of development will be crucial for gaining market trust and navigating the evolving regulatory environment.
For Healthcare Systems and Providers: A phased implementation strategy is recommended, beginning with low-risk, high-value administrative tasks like ambient scribing and automated patient support before moving to more complex clinical decision support systems. A strong governance framework is essential to manage the risks of "Shadow IT" and ensure staff are properly trained on the ethical and secure use of PH-LLMs.

Conclusion

The rise of Personal Health Large Language Models is not merely a passing trend but a fundamental paradigm shift in the delivery and management of healthcare. By moving beyond the limitations of general-purpose AI and traditional apps, PH-LLMs are introducing a new layer of intelligence that can reason over a patient's entire health profile to provide personalized, proactive, and continuous care.

While the market is experiencing explosive growth and attracting significant investment, the technology’s promise is inextricably linked to its ability to address complex ethical, regulatory, and social challenges. The controversies surrounding early pilot programs serve as a stark reminder of the high stakes involved. The future of HealthTech belongs to those who can master the delicate balance of driving innovation while building the most trusted, transparent, and accountable AI solutions for patients and providers alike.

Nelson Advisors > HealthTech and MedTech M&A

Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #MedTech#HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide